SMMT — Summit Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.87bn
- $10.28bn
Summit Therapeutics rises on $235 mln capital-raise
Brief: Summit Therapeutics Raises $235 Mln
U.S. STOCKS ON THE MOVE-Teekay, Brenmiller Energy, JetBlue
Summit surges as its cancer drug outdoes Merck's in China trial
U.S. STOCKS ON THE MOVE-Teekay, Brenmiller Energy, JetBlue
Newscasts - Trading at Noon: Wall Street recovers some of last week's losses
Summit shares hit record high as cancer drug tops Keytruda in China trial (updated)
U.S. STOCKS ON THE MOVE-Western Alliance Bancorp, Terns Pharma, Rezolute
U.S. STOCKS ON THE MOVE-Boeing, Tesla, Dell
Refile: Summit shares surge as cancer drug tops Keytruda in head-to-head study
Summit Therapeutics surges as its cancer drug outdoes Merck's
Brief: Summit Therapeutics Q2 Net Income USD -60.4 Million
Summit Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Summit Therapeutics Appoints Jeff Huber, Transformational Google And Grail Executive, To Its Board Of Directors
Brief: Summit Says It Raised $200 Million And Expands License Territories For Ivonescimab
China's Akeso hits near 3-year peak on Summit Therapeutics therapy success in study
Summit Therapeutics cancer therapy succeeds in late-stage China study (updated)
Summit Therapeutics cancer therapy succeeds in late-stage China study
Brief: Summit Therapeutics National Medical Products Administration Of China Approved Ivonescimab In Combination With Chemotherapy